TABLE OF CONTENTS

1.0 GOAL ............................................................................................................................ 1
2.0 CLINICAL DESCRIPTION ............................................................................................... 1
3.0 EPIDEMIOLOGY ............................................................................................................ 2
4.0 DEFINITIONS ................................................................................................................. 2
5.0 MANAGEMENT OF SPORADIC CASES .......................................................................... 4
  5.1 Identification of Cases................................................................................................ 4
  5.2 Management of Cases................................................................................................ 4
6.0 CONTACT MANAGEMENT ............................................................................................. 4
  6.1 Chemoprophylaxis of Close Contacts ....................................................................... 5
  6.2 Chemoprophylactic Agents for Close Contacts of Meningococcal Infection .......... 7
    Table 1: Chemoprophylactic Agents for Close Contacts of Meningococcal Infection ...... 7
  6.3 Immunoprophylaxis of Close Contacts ....................................................................... 9
    Table 2: Close Contacts Recommended to Receive Both Immunoprophylaxis (Immunization) and Chemoprophylaxis .......................................................... 9
      6.3.1 Immunoprophylaxis of Contacts of Serogroup C Disease ............................... 10
      6.3.2 Immunoprophylaxis of Contacts of Serogroup A, Y, or W-135 Disease .......... 11
      6.3.3 Immunoprophylaxis of Contacts of Serogroup B Disease ............................... 12
  6.4 Cadavers and Infectious Risk ....................................................................................12
7.0 STORAGE AND DISTRIBUTION OF MENINGOCOCCAL CHEMOPROPHYLACTIC
  AGENTS ..........................................................................................................................12
8.0 REPORTING .................................................................................................................13
9.0 INVASIVE MENINGOCOCCAL DISEASE IN TRAVELLERS ............................................13
10.0 MANAGEMENT OF CLUSTERS AND OUTBREAKS ......................................................14
  10.1 Definitions .............................................................................................................14
  10.2 Outbreak Identification........................................................................................14
  10.3 Outbreak Management........................................................................................15
  10.4 Immunoprophylaxis During an Outbreak...............................................................15
  10.5 Educate the Public .................................................................................................16
  10.6 Analyze the Outbreak .............................................................................................16
11.0 AUTHORITY .................................................................................................................16
12.0 REFERENCES ..............................................................................................................16
14.0 PROVISION OF CHEMOPROPHYLAXIS TO CLOSE CONTACTS OF INVASIVE
  MENINGOCOCCAL DISEASE ........................................................................................18
15.0 WORKSHEET: CHEMOPROPHYLAXIS/IMMUNOPROPHYLAXIS OF CONTACTS OF
  INVASIVE MENINGOCOCCAL DISEASE .....................................................................19
16.0 RIFAMPIN: CLIENT INFORMATION ........................................................................20
17.0 CIPROFLOXACIN: CLIENT INFORMATION ...............................................................21
18.0 CEFTRIAXONE (WITH LIDOCAINE): CLIENT INFORMATION .................................22
1.0 GOAL

The goal of meningococcal disease control is to prevent primary and secondary cases of invasive meningococcal disease by:

- Immunization of children, adolescents and high risk individuals according to BC immunization guidelines,
- Identification and management of contacts and ensuring that chemoprophylaxis and immunoprophylaxis are offered where indicated,
- Promptly instituting outbreak control measures, and
- Conducting surveillance to facilitate program monitoring and evaluation.

2.0 CLINICAL DESCRIPTION

*Neisseria meningitidis* (*N. meningitidis*) are Gram-negative diplococci with multiple serogroups. Serogroups A, B, C, Y, and W-135 \(^1\) are most commonly associated with invasive disease.

The incubation period ranges from 1 to 10 days, and is usually < 4 days.

The period of communicability is 7 days prior to the onset of symptoms to 24 hours after the initiation of appropriate antibiotic therapy.

Invasive meningococcal disease usually presents as meningitis and/or septicemia.

The signs of meningococcal meningitis are indistinguishable from those of acute meningitis caused by *Haemophilus influenzae* type b, *Streptococcus pneumoniae*, and some other bacterial pathogens. Signs of meningitis include sudden onset of fever, headache, and stiff neck, often accompanied by other symptoms such as nausea, vomiting, photophobia, and altered mental status.

Meningococcal sepsis occurs with or without meningitis and may progress rapidly to purpura fulminans (i.e., hypotension, fever, and disseminated intravascular coagulation), shock, and death.

Only invasive forms of the disease are reportable in BC and require identification and follow-up of contacts.

---

\(^1\) Due to a change in nomenclature, laboratory reporting of serogroup W-135 and 29E will be reported simply as serogroup W and serogroup 29, respectively (ref. Harrison).
Meningococcal bacteria are spread through direct contact with respiratory droplets from the nose and throat of an infected person.

* N. meningitidis can live in the nose and throat of an otherwise healthy person (asymptomatic carrier). Up to 5-10% of people may be asymptomatic carriers but less than 1% of those colonized will progress to invasive disease.

Diagnosis of meningococcal disease may be tentatively made based on findings of Gram-negative diplococci in an appropriate specimen (e.g., cerebrospinal fluid) of a person with clinically compatible signs and symptoms of meningococcal disease. Diagnosis is confirmed by the isolation of *N. meningitidis* from a normally sterile site or by identification of *N. meningitidis* DNA by PCR in a specimen obtained from a normally sterile site.

### 3.0 EPIDEMIOLOGY

Ten sporadic cases of invasive meningococcal disease (IMD) were reported in 2015, none with fatal outcomes. There were 6 cases of serogroup B, and 2 cases each of serogroup Y and W-135 disease. No cases had reported being immunized against the serogroup-specific disease. The median age of cases was 44 years, with four cases under 25 years of age (3 serogroup B and 1 serogroup W-135).

The incidence of IMD has decreased from 0.5 cases per 100,000 population in 2006 to 0.2 cases per 100,000 population in 2015. This is partly due to a decline in serogroup C from 0.1 to 0 cases per 100,000 population from 2006 to 2015, reflecting the impact of the infant and school-age meningococcal C conjugate immunization program beginning in September 2003. The remaining portion of the decline was due to lower incidence of serogroups A (2 travel associated cases in 2006 only), B, Y and non-typeable cases.

With declining incidence of serogroup C, serogroup B has become the most commonly reported serogroup with an incidence that ranged from 0.09 to 0.4 cases per 100,000 population per year between 2006 and 2015.

For the most up-to-date information, see the Annual Summaries of Reportable Diseases on the BCCDC website.

### 4.0 DEFINITIONS

**Confirmed Case**

Clinical evidence* of invasive disease with laboratory confirmation of infection:

- isolation of *N. meningitidis* from a normally sterile site (blood, CSF, joint, pleural or pericardial fluid)

OR
- demonstration of *N. meningitidis* DNA by an appropriately validated nucleic acid test (NAT) from a normally sterile site

**Probable Case**
Clinical evidence* of invasive disease with purpura fulminans or meningococcemia, with no other apparent cause, with non-confirmatory laboratory evidence:
- Gram-negative diplococci in the CSF

* Clinical illness associated with invasive meningococcal disease usually manifests as meningitis and/or septicemia, although other manifestations may be observed (e.g., orbital cellulitis, septic arthritis). Invasive disease may progress rapidly to purpura fulminans, shock and death.

**Close contact:** an individual who has had close contact with a case of meningococcal disease during the period of time in which the case was infectious (7 days prior to the onset of symptoms to 24 hours after the initiation of appropriate antibiotic therapy).

**Close contacts include:**
- household contacts of the case
- persons who share sleeping arrangements with the case
- persons who have had direct contamination of their nose or mouth with oral/nasal secretions of a case (i.e., kissing on the mouth; sharing toothbrushes, joints, cigarettes, eating utensils, mouth-guards, water bottles, or musical instrument mouthpieces)
- children and staff in child care and preschool facilities
- health care workers who have had intensive unprotected contact (without wearing a mask) with infected patients (e.g., intubating, resuscitating, or closely examining the oropharynx of patients)
- airline passengers sitting immediately on either side of the case (but not across the aisle) when the total time spent aboard the aircraft was at least 8 hours

**Sporadic case/Primary case:** Invasive disease in a single confirmed case that occurs in a community and with no evidence of an epidemiological link (by person, place or time) to another case.

**Co-primary cases:** Co-primary cases are two or more cases that occur among a group of close contacts with onset of illness separated by < 24 hours.

**Secondary case:** Invasive disease in a person that has had contact with a case and illness begins **more than 24 hours after** onset of illness in the index case. These cases may have acquired the disease from the index case or from a common source.
5.0 MANAGEMENT OF SPORADIC CASES

5.1 Identification of Cases

Investigate all laboratory and clinical reports of invasive meningococcal disease within 24 hours of receiving the report.

Public health staff should immediately notify the local Medical Health Officer of all confirmed and probable cases.

Obtain detailed information on each case to complete the Meningococcal Case Report Form. An initial report should be submitted to BCCDC within 24 hours of notification to public health.

Nasopharyngeal cultures are not useful as a diagnostic test in the confirmation of cases of invasive meningococcal disease because 5-10% of the well population will carry N. meningitidis as one of the nasopharyngeal flora at any one time without developing invasive disease.

Positive superficial or mucosal cultures (e.g., nasopharyngeal, eye, urethral) in the absence of symptoms of invasive disease do not require public health action.

5.2 Management of Cases

Ensure that all cases of invasive meningococcal disease are given one of the antibiotic agents listed in Table 1 Chemoprophylactic Agents for Close Contacts of Meningococcal Infection prior to discharge from hospital. This is not necessary if one of the listed agents had been received in the hospital. Some systemic antibiotics used in the treatment of invasive meningococcal disease do not eradicate colonization of N. meningitidis in the nose and mouth and therefore do not prevent secondary spread.

Send meningococcal isolates from all cases of invasive meningococcal disease to the BCCDC Public Health Laboratory for serogroup typing and susceptibility testing.

6.0 CONTACT MANAGEMENT

Identify all close contacts of the reported case within 24 hours of identification of the case. Refer to Section 4.0 Definitions for definition of close contacts.

Nasopharyngeal cultures should not be done as they are not useful in the identification and follow-up of close contacts; 5-10% of the well population will carry N. meningitidis as one of the nasopharyngeal flora at any given time without developing invasive disease.
6.1 Chemoprophylaxis of Close Contacts

Ensure that all close contacts are offered one of the chemoprophylactic agents specified in Table 1 Chemoprophylactic Agents for Close Contacts of Meningococcal Infection.

Utilize Provision of Chemoprophylaxis to Close Contacts of Invasive Meningococcal Disease form (Section 14.0) to communicate with MHO and/or Pharmacist regarding dispensing of chemoprophylactic agents.

The purpose of chemoprophylaxis is to eradicate nasopharyngeal colonization by *N. meningitidis* and thus prevent disease in contacts and transmission to susceptible persons. Levels of chemotherapeutic agents in nasal secretions may prevent acquisition of the organisms for a few days. Chemoprophylaxis is not effective in preventing disease once invasion of tissue has taken place.

Regardless of immunization status, chemoprophylaxis is indicated for all close contacts of cases of invasive meningococcal disease.

Administer chemoprophylaxis as soon as possible and preferably within 24 hours of diagnosis of the case. However, chemoprophylaxis is still recommended for up to 10 days (the incubation period) after the last contact with the case. Contact that occurs after the case has received 24 hours of appropriate antibiotic therapy is not a concern as the case is no longer infectious after this time.

Chemoprophylaxis is indicated for close contacts when there is strong clinical suspicion of invasive meningococcal disease in the index case, and laboratory confirmation is not possible within 24 hours (i.e., Gram-negative diplococci present and clinically compatible signs and symptoms of meningococcal disease).

Chemoprophylaxis is not recommended for casual contacts (i.e., school or classroom contacts, transportation and workplace contacts, or social contacts who are not close contacts).

Chemoprophylaxis is not recommended for emergency workers or health care contacts of cases, except for those workers who have had intensive unprotected contact (without wearing a mask) with infected patients (e.g., intubating, resuscitating, or closely examining the oropharynx). In those situations there is the possibility that the health care worker’s nose or mouth has been directly contaminated with oral or nasal secretions from the case of invasive meningococcal disease.

Public Health staff should consult and report to the BCCDC Communicable Diseases and Immunization Service when a case or the close contacts of a case traveled outside the province of BC while infectious (during working hours, call 604-707-2519; after hours, call 604-875-2161 or 1-888-300-3088 for geographies outside of the Lower Mainland local calling area).
Advise close contacts to complete the full course of antibiotic agents provided to ensure optimal effectiveness.

Advise close contacts about the symptoms of invasive meningococcal disease (i.e., fever, headache, stiff neck, petechial rash) and instruct anyone who becomes symptomatic to seek prompt medical attention.
### Chemoprophylactic Agents for Close Contacts of Meningococcal Infection

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Contraindications</th>
<th>Counseling/ Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rifampin</td>
<td>Provided free for cases and contacts</td>
<td>Prematurity. Jaundice. Many HIV antiretroviral medications. Consult HIV specialist or pharmacist telephone: 1-800-665-7677.</td>
<td>Advise client to take, preferably on an empty stomach, one hour before or two hours after eating food.</td>
</tr>
<tr>
<td></td>
<td><strong>Infants &lt; 1 month of age:</strong> 5 mg/kg per dose PO Q12Hx 4 doses</td>
<td></td>
<td>Advise pregnant women to consult their physician before taking rifampin as it is generally not recommended in pregnancy.</td>
</tr>
<tr>
<td></td>
<td><strong>Children ≥ 1 month of age:</strong> 10 mg/kg (to maximum 600 mg) per dose PO Q12Hx 4 doses</td>
<td></td>
<td>Advise against wearing soft contact lenses to protect against permanent staining. Urine, tears, sputum and sweat can be stained red-orange.</td>
</tr>
<tr>
<td></td>
<td><strong>Adults (≥ 18 years of age): 600 mg PO Q12h X 4 doses</strong></td>
<td>Drug Interactions: Rifampin induces certain cytochrome P-450 enzymes; its coadministration with other drugs metabolized through cytochrome P-450 enzymes may require adjustment of dosing when starting or stopping concomitantly administered rifampin. Refer to product monograph for list of relevant drugs. Alternately, consider use of one of the alternate two antibiotics.</td>
<td>Advise client to use alternate contraceptive measures. Rifampin may interfere with the efficacy of estrogen-containing contraceptives.</td>
</tr>
</tbody>
</table>

**Note:** table continued on next page.

---

1 If a child is unable to swallow rifampin capsules and a rifampin suspension cannot be prepared or accessed from a hospital pharmacy, advise client to obtain a prescription for rifampin suspension from the assessing physician and to present the prescription to a community pharmacy to be dispensed. The community pharmacy should then submit the invoice to BCCDC Pharmacy for payment.

2 [http://www.cfenet.ubc.ca/healthcare-resources/reach-line](http://www.cfenet.ubc.ca/healthcare-resources/reach-line)

Table 1: Chemoprophylactic Agents for Close Contacts of Meningococcal Infection (cont’d)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage</th>
<th>Contraindications</th>
<th>Counseling/ Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciprofloxacin</td>
<td>Those ≥ 18 years of age: A single dose of 500 mg PO</td>
<td>Pregnancy, lactation, and use in children &lt; 18 years old. Hypersensitivity reaction when used previously. Hypersensitivity to other fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin, gatifloxacin).</td>
<td>Advise client to avoid concurrent use of antacids and iron products. If concurrent use cannot be avoided, advise client to take antacid at least 6 hours before or 2 hours after ciprofloxacin. Advise client to use caution about operating an automobile or machinery that requires mental alertness or coordination. Ciprofloxacin may cause dizziness and lightheadedness. Advise client to seek medical advice if signs of drug hypersensitivity develop.</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>Children ≥ 12 years and adults: A single dose of 250 mg IM</td>
<td>Hypersensitivity to penicillins or penicillin derivatives or to local anesthetics (especially lidocaine).</td>
<td>Advise client regarding possible local reactions. (i.e., pain, induration, and tenderness at injection site). Advise client about diarrhea and other GI related adverse events. Ceftriaxone is the recommended drug for pregnant women and the alternative for persons who cannot tolerate oral medication. Advise client to seek medical advice if signs of drug hypersensitivity develop.</td>
</tr>
<tr>
<td></td>
<td>Children &lt; 12 years: A single dose of 125 mg IM</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dilute in 1% lidocaine to reduce pain at injection site</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
6.3 Immunoprophylaxis of Close Contacts

Identify those close contacts who are at highest risk of meningococcal disease and for whom immunization is indicated in addition to chemoprophylaxis.

<table>
<thead>
<tr>
<th>Table 2: Close Contacts Recommended to Receive Both Immunoprophylaxis (Immunization) and Chemoprophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>• household contacts of the case</td>
</tr>
<tr>
<td>• persons who share sleeping arrangements with the case</td>
</tr>
<tr>
<td>• persons who have had direct contamination of their nose or mouth with oral/nasal secretions of a case (i.e., kissing on the mouth; sharing toothbrushes, eating utensils, cigarettes, mouth-guards, water bottles, or musical instrument mouthpieces)</td>
</tr>
<tr>
<td>• children and staff in child care and preschool facilities.</td>
</tr>
</tbody>
</table>

Household contacts in particular have an increased risk of re-exposure to the bacteria that persists for up to 1 year after disease in the index case and beyond any protection from chemoprophylaxis. In general, this prolonged risk is not seen among other contacts that do not have ongoing exposure.

Assess the immunization status of close contacts who are recommended to receive immunoprophylaxis in addition to chemoprophylaxis. Ascertain whether meningococcal vaccine(s) has been received in the past including type of vaccine, number of doses, and age or date at time of vaccine administration. If serogroup result is not available at the time of chemoprophylaxis, inform close contacts that vaccine may be recommended when laboratory results are available.

Revaccination criteria for those previously vaccinated against IMD:

• Those previously vaccinated with a serogroup that differs from the index case or outbreak strain should be vaccinated immediately with the appropriate vaccine (as outlined below).

• Those previously vaccinated with a conjugate vaccine of the serogroup that is the same as the index case or outbreak strain should be revaccinated with the appropriate vaccine if:
  o last dose of vaccine was given prior to one year of age and more than 4 weeks has passed since their last dose; OR
  o they have an underlying medical condition\(^1\) that puts them at risk for meningococcal disease and more than 4 weeks has passed since their last dose of vaccine; OR

---

\(^{1}\) The following medical conditions put individuals at increased risk for meningococcal disease: functional or anatomic asplenia, including sickle cell disease; congenital complement, properdin, factor D or primary antibody deficiencies; acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab (Soliris®); hematopoietic stem cell transplant (HSCT); solid organ or islet cell transplant; and HIV infection.
they have no underlying medical condition\textsuperscript{1} that puts them at risk for meningococcal disease, and last dose of vaccine was given after 1 year of age and more than one year has passed since their last dose.

Complete Section 15.0 Worksheet: Chemoprophylaxis/Immunoprophylaxis of Contacts of Invasive Meningococcal Disease.

### 6.3.1 Immunoprophylaxis of Contacts of Serogroup C Disease

When the case is confirmed as due to serogroup C, use a monovalent meningococcal C conjugate vaccine to vaccinate close contacts as follows:

<table>
<thead>
<tr>
<th>Age at presentation</th>
<th>Recommended schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 months to 11 months of age</td>
<td>Unvaccinated: give 1 dose immediately after exposure then complete routine series</td>
</tr>
<tr>
<td></td>
<td>Previously vaccinated: revaccinate if at least 4 weeks since last dose, then complete routine series</td>
</tr>
<tr>
<td>12 months of age and older</td>
<td>Unvaccinated: give 1 dose immediately after exposure</td>
</tr>
<tr>
<td></td>
<td>Previously vaccinated: if previously vaccinated at less than one year of age or at high risk of IMD due to underlying medical condition, give 1 dose of Men-C-C if at least 4 weeks following last dose; otherwise revaccinate if at least 1 year since last dose.</td>
</tr>
</tbody>
</table>

NeisVac-C\textsuperscript{®} is the preferred product for children 12 months of age and younger.

\textsuperscript{1} The following medical conditions put individuals at increased risk for meningococcal disease: functional or anatomic asplenia, including sickle cell disease; congenital complement, properdin, factor D or primary antibody deficiencies; acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab (Soliris\textsuperscript{®}); hematopoietic stem cell transplant (HSCT); solid organ or islet cell transplant; and HIV infection.
6.3.2 Immunoprophylaxis of Contacts of Serogroup A, Y, or W-135 Disease

If previously vaccinated with only Men-C-C, give Men-C-ACYW-135 as for unvaccinated person regardless of when Men-C-C was previously given. In contacts who are less than 2 years of age, use Men-C-ACYW-135-CRM$_{197}$ (Menveo®) vaccine.

<table>
<thead>
<tr>
<th>Age at presentation</th>
<th>Recommended Schedule for post-exposure prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 to 11 months of age</td>
<td>Menveo® only</td>
</tr>
<tr>
<td>Unvaccinated: 2 doses given 8 weeks apart* with a 3rd dose between 12 and 23 months of age and at least 8 weeks* after the previous dose</td>
<td></td>
</tr>
<tr>
<td>Previously vaccinated: revaccinate with one dose if at least 4 weeks since last dose, then complete series</td>
<td></td>
</tr>
<tr>
<td>12 to 23 months of age</td>
<td>Menveo® only</td>
</tr>
<tr>
<td>Unvaccinated: 2 doses at least 8 weeks apart</td>
<td></td>
</tr>
<tr>
<td>Previously vaccinated: if previously vaccinated at less than one year of age or at high risk of IMD due to underlying medical condition, revaccinate with one dose if at least 4 weeks since last dose; otherwise revaccinate with one dose if at least 1 year since last dose.</td>
<td></td>
</tr>
<tr>
<td>2 years of age and older</td>
<td>Menveo®, Menactra®, or Nimenrix®</td>
</tr>
<tr>
<td>Unvaccinated: 1 dose immediately after exposure</td>
<td></td>
</tr>
<tr>
<td>Previously vaccinated: if previously vaccinated at less than one year of age or at high risk of IMD due to underlying medical condition, revaccinate with one dose if at least 4 weeks since last dose; otherwise revaccinate with one dose if at least 1 year since last dose.</td>
<td></td>
</tr>
</tbody>
</table>

*Minimum interval of 4 weeks if rapid protection is required such as in the event of hyperendemic rates of disease locally.

Men-C-ACYW-135-CRM$_{197}$ (Menveo®) vaccine has been found to be immunogenic in infants and toddlers; however infants vaccinated at less than one year of age show a waning immune response indicating the need for a booster dose in the second year of life.

In the unlikely event that a contact has received meningococcal polysaccharide vaccine against the serogroup in question within the prior 6 months, a conjugate meningococcal vaccine for post-exposure prophylaxis need not be administered. If 6 months or more has passed, the appropriate conjugate vaccine should be offered.

---

¹ Due to a change in nomenclature, laboratory reporting of serogroup W-135 and 29E will be reported simply as serogroup W and serogroup 29, respectively (ref. Harrison).
6.3.3 Immunoprophylaxis of Contacts of Serogroup B Disease

Meningococcal B vaccine for close contact immunoprophylaxis can be ordered from BCCDC Pharmacy using the Meningococcal B Vaccine Form. Immunize contacts 2 months and older with meningococcal B vaccine (Bexsero®) according to the following schedule. For close contacts, the risk of re-exposure may persist for up to one year therefore it is recommended that the full series be completed.

<table>
<thead>
<tr>
<th>Age at presentation</th>
<th>Recommended schedule for post-exposure prophylaxis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infants 2 to 5 months</td>
<td>Unvaccinated: 1 dose immediately after exposure; then revaccinate with 2 more doses</td>
</tr>
<tr>
<td>of age, inclusive</td>
<td>with at least a 4 week interval between doses.</td>
</tr>
<tr>
<td></td>
<td>Previously vaccinated: 1 dose immediately after exposure</td>
</tr>
<tr>
<td>Infants 6 to 11 months</td>
<td>Unvaccinated: 1 dose immediately after exposure; then revaccinate with a single dose</td>
</tr>
<tr>
<td>of age, inclusive</td>
<td>after at least 8 weeks.</td>
</tr>
<tr>
<td>Children 12 months</td>
<td>Unvaccinated: 1 dose immediately after exposure; then revaccinate with a single dose</td>
</tr>
<tr>
<td>to 10 years of age, inclusive</td>
<td>after at least 8 weeks.</td>
</tr>
<tr>
<td>Individuals 11 years</td>
<td>Unvaccinated: 1 dose immediately after exposure then revaccinate with a single dose</td>
</tr>
<tr>
<td>of age and older</td>
<td>after at least 4 weeks.</td>
</tr>
<tr>
<td></td>
<td>Previously vaccinated: 1 dose immediately after exposure</td>
</tr>
</tbody>
</table>

6.4 Cadavers and Infectious Risk

Follow routine infection control practices when handling a cadaver.

While cadavers with meningococcal disease have traditionally been considered a possible source of infection risk, in cases where the deceased person had been treated with an effective antibiotic for at least 24 hours prior to death, any risk is likely to be very low.

This does not include embalming and autopsy procedures, which are regulated by the relevant professional organizations.

7.0 Storage and Distribution of Meningococcal Chemoprophylactic Agents

The location of the storage site(s) and means of distribution of the chemoprophylactic agents to cases and close contacts of a case of meningococcal disease is a local health unit decision. Regardless of the means adopted, there must be no patient charges for the drugs and no fees charged for the service.
To order bulk supplies of chemoprophylactic drugs contact the Product Distribution Centre. To order pre-packaged dosage defined units, contact BCCDC Pharmacy. Order forms may be obtained from BCCDC Pharmacy.

8.0 REPORTING

Fax an initial completed Meningococcal Case Report Form to Communicable Diseases and Immunization Service, BCCDC (fax: 604-707-2515) within 24 hours of the report of the case. Enter confirmed and probable cases of invasive meningococcal disease in the electronic public health information system used for reportable disease notification.

When the remaining information on the Case Report Form is available (e.g., serogroup, risk factors, meningococcal vaccine history, outcome) update the case report form and resend by fax to Communicable Diseases and Immunization Service, BCCDC (fax: 604-707-2515). As well, complete this information in the electronic public health information system used for reportable disease notification.

9.0 INVASIVE MENINGOCOCCAL DISEASE IN TRAVELLERS

If an invasive case has been identified in an individual who travelled out of province while infectious, consider the need and possibility to identify out of province contacts and offer immuno/chemoprophylaxis. This will depend on the type of travel (e.g., prolonged air travel with adjacent passengers), and the type of exposure (e.g., household-type contact).

If such contacts can be identified from the history, notify this information immediately to the Communicable Diseases and Immunization Service, BCCDC, in order to initiate out of province notification (during working hours, call 604-707-2519; after hours, call 604-875-2161 or 1-888-300-3088 for geographies outside of the Lower Mainland local calling area).

A review of publications related to meningococcal disease cases acquired during transport identified a single case resulting from transmission while aboard aircraft; however current surveillance systems may not detect secondary cases resulting specifically from air travel. Therefore the theoretical risk of transmission during air travel should be considered. Based on expert opinion and the extrapolation of data on secondary transmission of tuberculosis cases aboard aircrafts, it is recommended that contact tracing be initiated if:

- the case traveled during their infectious period
- the flight occurred within the previous 10 days
- the total time spent aboard the aircraft was at least 8 hours, including ground time on the tarmac.

Aircraft passenger manifests should be requested promptly as these are not retained indefinitely by the airline industry.

Attempt to trace, contact, and offer antimicrobial chemoprophylaxis to:

- Persons traveling with the index case who have had prolonged close contact (e.g., household members, roommates). These persons should also be offered vaccine.
• Passengers who were sitting immediately on either side of the index case (but not across the aisle).
• Passengers and flight staff who have had direct contact with the respiratory secretions of the index case.

The above individuals may be at an increased risk as bacteria transmitted through respiratory droplets can be propelled short distances (< 1 metre) during coughing and sneezing.

10.0 MANAGEMENT OF CLUSTERS AND OUTBREAKS

10.1 Definitions

An outbreak is defined as increased transmission of *N. meningitidis* in a population, manifested by an increase in cases of the same serogroup.

Outbreaks can be subdivided into organization based or community based outbreaks:

**Organization Based**
- Increased transmission of *N. meningitidis* in an organization or institution with two or more cases of the same serogroup occurring within a 4 week interval. This includes restricted populations, such as schools, day cares, sports groups or social groups, as well as nursing homes or long term care facilities.

**Community Based**
- Increased transmission of *N. meningitidis* in a community, with three or more confirmed cases of the same serogroup occurring within a 3 month interval AND an age-specific incidence OR specific community population incidence of approximately 10 per 100,000 where there is an absence of an epidemiologic link between cases. This is not an absolute threshold and should be considered in the context of other factors.

A cluster is defined as 2 or more cases of the same serogroup that are closer in time and space than expected for the population or group under surveillance.

10.2 Outbreak Identification

The Medical Health Officer, CDC Coordinator and/or other relevant staff will compare the detailed information obtained on all cases to determine associations and/or identify high-risk groups that may require control interventions.

The Medical Health Officer or designate should immediately consult the Immunization Program and Vaccine Preventable Diseases Service, BCCDC when an increase in the incidence of invasive meningococcal disease occurs or is suspected. A collaborative review of all available information will help determine whether the increased incidence constitutes an outbreak.
Inform local laboratories to send meningococcal isolates from all cases of invasive disease to the BCCDC Public Health Laboratory for serogroup typing and susceptibility testing. BCCDC Public Health Laboratory forwards all isolates to the National Microbiology Laboratory, Health Canada, for further phenotypic typing and genetic analysis. The presence of a common vaccine-preventable serogroup is a key consideration when evaluating the need for immunization during an outbreak.

10.3 Outbreak Management

The Medical Health Officer or designate should notify local hospital emergency departments, laboratories, infection control departments, and physicians of the outbreak emphasizing the importance of:

- early diagnosis of fever, headache, stiff neck, or petechial rash
- confirmation of all suspect cases with appropriate diagnostic tests (culture of blood, CSF, or other sterile site)
- prompt notification of all suspect cases to the appropriate health unit staff
- respiratory isolation of cases and contacts for 24 hours following the start of antibiotics.

Review all recent (within past 2 weeks), and ongoing absenteeism when the cluster or outbreak occurs in a school or daycare. Identify any individual with signs and symptoms of meningococcal disease and refer for prompt diagnosis and treatment.

In the management of clusters/outbreaks, chemoprophylaxis is to be used only for close contacts of confirmed and probable cases. There is no evidence to support the provision of widespread chemoprophylaxis for persons who are not close contacts.

10.4 Immunoprophylaxis During an Outbreak

**Immunization is considered** when epidemiological evidence suggests an outbreak is occurring or there is a cluster of cases in a delineated population caused by a vaccine-preventable serogroup.

**Immunization is recommended** when at least three cases of the same vaccine-preventable serogroup are reported in a delineated population during a 3 month period, and the primary attack rate is 10 per 100,000 of the population.

The decision to use meningococcal vaccine as an outbreak control measure should be made in consultation by the regional MHO with BCCDC Immunization Program and the Provincial Health Officer.

Immunize the identified target populations as quickly as possible once a decision has been made to use vaccine as a control measure. Protective antibody levels are achieved 7-10 days after receiving the vaccine. Vaccination can help stop outbreaks by providing protection to individuals; additionally, the conjugate meningococcal C vaccines reduce nasopharyngeal carriage and through this means, provide indirect protection to unimmunized individuals in the community.
There is no need for routine re-immunization of children or adults once the outbreak is over.

10.5 Educate the Public

Educate the public during an outbreak about the need to reduce exposure to droplet infection and to reduce direct contact with the oral and nasal secretions of others.

Educate the public regarding the symptoms of invasive meningococcal disease (i.e., fever, headache, stiff neck, and petechial rash). Advise all symptomatic individuals to seek prompt medical attention.

Consider deferring community events lasting 4 hours or longer and involving large numbers of people of the target population. Consult with the MHO and/or BCCDC.

10.6 Analyze the Outbreak

Review the effectiveness of the local control measures and revise local protocols as necessary.

Following an outbreak, an epidemiological analysis of events provides a useful local reference.

11.0 AUTHORITY

Public Health Act (SBC 2008) and Communicable Disease Regulation

12.0 REFERENCES


14.0 PROVISION OF CHEMOPROPHYLAXIS TO CLOSE CONTACTS OF INVASIVE MENINGOCOCCAL DISEASE

Instructions:
- Public Health Nurse completes non-shaded sections of form and forwards to MHO
- MHO forwards form to dispensing Pharmacist OR returns to Public Health Nurse for provision of chemoprophylactic agent
- Person providing drug to client(s) completes shaded section of form

This form authorizes the pharmacist OR PHN to provide the indicated chemoprophylactic agent

<table>
<thead>
<tr>
<th>Name of Contact (Surname/ Given name)</th>
<th>PHN</th>
<th>Age or DOB (y/m/d)</th>
<th>Wt (kg)</th>
<th>Contraindications?</th>
<th>Name of Chemoprophylactic Agent to be Provided</th>
<th>Date Client Provided Drug (y/m/d)</th>
<th>Name of Person Providing Drug (Surname/ Given Name)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>♠ Drug</th>
<th>Dosage</th>
<th>♦ Contraindications</th>
</tr>
</thead>
</table>
| Rifampin | Infants <1 month of age: 5 mg/kg per dose PO Q12H x 4 doses  
Children ≥ 1 month of age: 10 mg/kg (to maximum 600 mg) per dose PO Q12H x 4 doses  
Adults (≥ 18 years of age): 600 mg PO Q12h X 4 doses | Prematurity  
Presence of jaundice  
Many HIV antiretroviral medications.  
History of an allergic reaction when used previously. |
| Ciprofloxacin | Those ≥ 18 yrs of age: A single dose of 500 mg PO | Pregnancy, lactation  
Use in children < 18 years old  
Hypersensitivity reaction when used previously  
Hypersensitivity to other fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin, gatifloxacin) |
| Ceftriaxone | Adults and children ≥ 12 years of age: A single dose of 250 mg IM  
Children < 12 yrs: A single dose of 125 mg IM | Hypersensitivity to penicillins or penicillin derivatives or to local anesthetics (especially lidocaine). |
### 15.0 WORKSHEET: CHEMOPROPHYLAXIS/IMMUNOPROPHYLAXIS OF CONTACTS OF INVASIVE MENINGOCOCCAL DISEASE

Name of case: ______________________________ (Surname)          (Given name)

Period of communicability: From _____/___/___ to _____/___/___ yyyy/mm/dd                yyyy/mm/dd

Person completing worksheet: ______________________________ (Surname)  (Given name)

<table>
<thead>
<tr>
<th>Name of Contact (Given name/ Surname)</th>
<th>Public Health Number (PHN)</th>
<th>Age or DOB (y/m/d)</th>
<th>Wt (kg)</th>
<th>Contra-indications? (see below)</th>
<th>Name of Chemoprophylactic Agent Recommended</th>
<th>Antibiotic Received</th>
<th>Vaccine Given?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Yes  No</td>
<td>Rifampin Cipro Ceftriaxone</td>
<td>Yes No</td>
<td>Men- C- C Men-C- A, C, Y, W-135 Men B</td>
</tr>
<tr>
<td>Phone number</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rifampin</td>
<td>Prematurity Presence of jaundice Receipt of many HIV antiretroviral medications History of an allergic reaction when used previously.</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Pregnancy, lactation, and use in children &lt; 18 years old Hypersensitivity reaction when used previously. Hypersensitivity to other fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin, garifloxacin)</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>Hypersensitivity to penicillins or penicillin derivatives or to local anesthetics (especially lidocaine).</td>
</tr>
</tbody>
</table>
16.0 RIFAMPIN: CLIENT INFORMATION

**WHY** is this medicine prescribed?
Rifampin is an antibiotic prescribed to prevent the spread of meningococcal infection when a person is exposed to meningococcal bacteria (*Neisseria meningitidis*). Meningococcal disease can be spread by close contact with an infected person. Close contact means living in the same household; sharing sleeping arrangements; or sharing saliva through activities such as using the same eating utensils, kissing, drinking from the same glass or water bottle, or sharing joints, cigarettes, musical mouthpieces, or lipstick.

**HOW** is this medicine taken?
To prevent meningococcal infection, rifampin is usually taken as a short course of 1 - 2 capsules by mouth twice a day for 2 days. It is best to take these capsules 12 hours apart, on an empty stomach. It is important that you finish this course of therapy. The person prescribing this medication will determine your dose of rifampin based on your age and weight. For infants and young children unable to swallow capsules, a Pharmacist can prepare the rifampin dose as a liquid suspension.

**WHO** should NOT take this medicine?
- Premature infants
- Those who are allergic to it
- Those who have jaundice
- Those on many HIV antiretroviral medications.

Women who are breastfeeding can take rifampin, as only small amounts are secreted into breast milk.

**WHAT** precautions should you be aware of before taking rifampin?
- If you are pregnant, consult your doctor before taking rifampin.
- Tell your public health nurse, pharmacist, or doctor if you are taking any other medicines.
- If you are taking warfarin, inform your doctor that you are taking rifampin because you will need to be more closely monitored.
- Rifampin may cause estrogen-containing contraceptives (birth control pills) and the contraceptive patch (EVRA®) to be less effective. You will need to use a second form of contraception (e.g., condoms) to prevent pregnancy.
- Rifampin may color urine and tears a red-orange color. This is harmless. However, since this may cause permanent staining of soft contact lenses, do NOT wear soft contact lenses until you have finished taking rifampin.
- Rifampin may cause drowsiness. Do not drive or operate dangerous machinery until you know how the drug affects you.

**WHAT** side effects can rifampin cause?
Side effects are uncommon when rifampin is taken in this four-dose course, but may include the following:
- Reddish-orange discoloration of your urine, feces, tears, or saliva. This discoloration is harmless.
- Stomach upset
- Headache. **Note**: Severe headache and stiff neck may be signs of a meningococcal infection. **Tell your doctor immediately if you experience any of these after taking rifampin:**
  - Skin rash, itching, or hives
  - Difficulty breathing or swallowing
  - Swelling of the face or throat
  - Persistent upset stomach, vomiting, or diarrhea
  - Fever or chills
  - Sore mouth or throat
  - Muscle or bone pain
  - Yellowing of the skin or eyes
17.0 **CIPROFLOXACIN: CLIENT INFORMATION**

**Why is this medicine prescribed?**
- Ciprofloxacin is an antibiotic prescribed to prevent the spread of meningococcal infection when a person is exposed to meningococcal bacteria (*Neisseria meningitidis*). Meningococcal disease can be spread by close contact with an infected person. Close contact means living in the same household; sharing sleeping arrangements; or sharing saliva through activities such as using the same eating utensils, drinking from the same glass or water bottle, kissing, or sharing joints, cigarettes, musical mouthpieces, or lipstick.

**HOW is this medicine taken?**
- Ciprofloxacin comes as a 500 mg tablet and is taken by mouth as a single dose with a full glass of water preferably one hour before or two hours after a meal.
- Do not take at the same time as dairy products, calcium supplements, iron supplements, zinc supplements or antacids containing magnesium or aluminum hydroxide. If you must use these products when taking ciprofloxacin, take them at least 6 hours before or 2 hours after taking ciprofloxacin.

**WHAT precautions should be taken before taking ciprofloxacin?**
Tell your pharmacist, public health nurse, or doctor:
- If you are less than 18 years of age.
- If you are pregnant, plan to become pregnant or are breastfeeding.
- If you have a drug allergy especially to ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, gatifloxacin, norfloxacin, or nalidixic acid.

**WHAT drug(s) may interact with ciprofloxacin?**
- Antacids
- Calcium, zinc and Iron supplements
- Theophylline
- Phenyltoin
- Warfarin

**WHAT side effects can ciprofloxacin cause?**
- Upset stomach
- Diarrhea
- Vomiting
- Stomach pain
- Headache
- Restlessness and nervousness
- Dizziness and light headedness
- Swelling of the face or throat

**WHEN to contact your doctor?**
Report any allergic, unusual or alarming side effects immediately to your doctor such as:
- Skin rash, itching, hives
- Difficulty breathing or swallowing
- Swelling of the face or throat

**WHAT precautions should be followed when taking ciprofloxacin?**
- Keep out of the sun; you may be more sensitive to sunlight.
- If you experience dizziness or lightheadedness, do not drive or operate machinery.
- Make sure you stay well hydrated while taking ciprofloxacin. Drink plenty of water.
18.0 CEFTRIAXONE (WITH LIDOCAINE): CLIENT INFORMATION

WHY is ceftriaxone prescribed?
Ceftriaxone is an antibiotic prescribed to prevent the spread of meningococcal infection when a person is exposed to meningococcal bacteria (*Neisseria meningitidis*). Meningococcal disease can be spread by close contact with an infected person. Close contact means living in the same household; sharing sleeping arrangements; or sharing saliva through activities such as using the same eating utensils, kissing, drinking from the same glass or water bottle, or sharing joints or cigarettes, musical mouthpieces, or lipstick.

HOW is this medicine used?
- Ceftriaxone when used to prevent meningitis is given as a single dose injection into the muscle.
- The medicine is mixed with lidocaine (a local anesthetic) to reduce pain associated with the injection.

WHO should use this medication?
- Ceftriaxone is free for household and other close contacts of people with invasive meningococcal infection.
- It is safe for people of all ages, including:
  - Children and infants – the dose for children less than 12 years old is 125 mg; the dose for those 12 years of age and older is 250 mg.
  - Pregnant and breastfeeding women.

WHO should NOT take this medication?
- Do NOT use ceftriaxone if you have a known allergy to it (or to local anesthetics).
- Do NOT use ceftriaxone until you have reviewed your allergy history with the administering nurse or physician, especially allergy to a class of antibiotics known as cephalosporins [eg., cefadroxil (Ceclor), cephalexin (Keflex)] or penicillins. If you have a medication allergy that may affect whether or not you receive this single dose of ceftriaxone, the public health nurse will consult with a Medical Health Officer or one of the hospital pharmacists.

WHAT precautions should be followed when taking ceftriaxone?
- PLEASE WAIT in the health unit or clinic for at least 15 minutes after the injection has been given.

WHAT side effects can ceftriaxone cause?
- Side effects are uncommon when only a single injection is used. Possible side effects include:
  - Diarrhea
  - Vomiting
  - Stomach pain
  - Upset stomach

- Inform your doctor immediately if you develop any of the following within 48 hours of receiving your single dose of ceftriaxone:
  - Skin rash
  - Itching
  - Hives
  - Difficulty breathing or swallowing
  - Swelling of the face and throat
  - Sore mouth or throat.